Cytek Biosciences Inc (NASDAQ:CTKB) — Market Cap & Net Worth
Market Cap & Net Worth: Cytek Biosciences Inc (CTKB)
Cytek Biosciences Inc (NASDAQ:CTKB) has a market capitalization of $542.48 Million ($542.48 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12100 globally and #2852 in its home market, demonstrating a 8.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cytek Biosciences Inc's stock price $4.62 by its total outstanding shares 128550136 (128.55 Million). Analyse Cytek Biosciences Inc cash conversion from operations to see how efficiently the company converts income to cash.
Cytek Biosciences Inc Market Cap History: 2021 to 2026
Cytek Biosciences Inc's market capitalization history from 2021 to 2026. Data shows change from $2.10 Billion to $593.90 Million (-25.43% CAGR).
Index Memberships
Cytek Biosciences Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #312 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1152 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.54 Trillion | 0.03% | #546 of 602 |
Weight: Cytek Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cytek Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cytek Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.22x
Cytek Biosciences Inc's market cap is 3.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.10 Billion | $127.95 Million | $3.00 Million | 16.40x | 699.08x |
| 2022 | $1.31 Billion | $164.04 Million | $2.58 Million | 8.00x | 509.51x |
| 2023 | $1.17 Billion | $193.01 Million | -$12.15 Million | 6.07x | N/A |
| 2024 | $834.29 Million | $200.45 Million | -$6.02 Million | 4.16x | N/A |
| 2025 | $649.18 Million | $201.49 Million | -$66.54 Million | 3.22x | N/A |
Competitor Companies of CTKB by Market Capitalization
Companies near Cytek Biosciences Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Cytek Biosciences Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
Cytek Biosciences Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Cytek Biosciences Inc's market cap moved from $2.10 Billion to $ 593.90 Million, with a yearly change of -25.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $593.90 Million | -8.51% |
| 2025 | $649.18 Million | -22.19% |
| 2024 | $834.29 Million | -28.84% |
| 2023 | $1.17 Billion | -10.68% |
| 2022 | $1.31 Billion | -37.44% |
| 2021 | $2.10 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Cytek Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $542.48 Million USD |
| MoneyControl | $542.48 Million USD |
| MarketWatch | $542.48 Million USD |
| marketcap.company | $542.48 Million USD |
| Reuters | $542.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more